Divesiran Phase 1 Data Shows Durable Efficacy, Quality-of-Life Improvements in Polycythemia Vera
SLN sits 59% above its 52-week low of $4.19 on light trading volume (0.2× avg).
Summary
Silence Therapeutics announced positive Phase 1 data for divesiran in polycythemia vera, demonstrating durable efficacy and improved quality-of-life, with Phase 2 results anticipated in August 2026.
Key Events · Product Development and Regulatory · SLN
-
Positive Phase 1 Divesiran Data
Follow-up data from the SANRECO study showed durable reductions in phlebotomy use and improvements in quality-of-life for polycythemia vera patients treated with divesiran.
-
Potential Best-in-Class Profile
The data reinforces divesiran's potential as a best-in-class siRNA therapy for PV, with sustained hematocrit control and robust symptom improvement.
-
Phase 2 Results Expected August 2026
The ongoing Phase 2 SANRECO study, evaluating Q6W and Q12W dosing regimens, remains on track for topline results in August 2026.
Analysis · SLN · Life Sciences
Silence Therapeutics reported strong follow-up and quality-of-life data from its Phase 1 SANRECO study for divesiran in polycythemia vera. The data highlights durable reductions in phlebotomy use and improvements in patient symptoms, supporting the drug's potential as a best-in-class therapy. These positive results de-risk the program and build anticipation for the Phase 2 topline data expected in August 2026.
At the time of this filing, SLN was trading at $6.68 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $283.4M. The 52-week trading range was $4.19 to $8.40. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.